Edgar Filing: CONCERT PHARMACEUTICALS, INC. - Form 4

CONCERT PHARMACEUTICALS, INC.

Form 4

February 21, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB

3235-0287 Number:

OMB APPROVAL

January 31, Expires: 2005 Estimated average

burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

Form 5 obligations may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person * **BROOKSIDE CAPITAL**

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

MANAGEMENT LLC

CONCERT PHARMACEUTICALS,

(Check all applicable)

INC. [CNCE]

(Month/Day/Year)

3. Date of Earliest Transaction

02/19/2014

Director X 10% Owner _ Other (specify Officer (give title below)

JOHN HANCOCK TOWER, 200 **CLARENDON STREET**

(First)

(Middle)

(Zip)

(Street)

(State)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person

BOSTON, MA 02116

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	Table 1 - Non-Derivative Securities Acquired, Disposed of, of Deficiency Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					(A) or		Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)	
			Code V	Amount	(D)	Price			See
COMMON STOCK	02/19/2014		C	761,062	A	<u>(1)</u>	793,851	I	Footnote (2)
COMMON STOCK	02/19/2014		C	353,982	A	(1)	1,147,833	I	See Footnote
COMMON STOCK	02/19/2014		P	350,000	A	\$ 14	1,497,833	I	See Footnote

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: CONCERT PHARMACEUTICALS, INC. - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Am Underlying Sec (Instr. 3 and 4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title
SERIES B CONVERTIBLE PREFERRED STOCK	(1)	02/19/2014		С	4,300,000	<u>(1)</u>	(3)	COMMON STOCK
SERIES C CONVERTIBLE PREFERRED STOCK	(1)	02/19/2014		C	2,000,000	<u>(1)</u>	(3)	COMMON STOCK

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
BROOKSIDE CAPITAL MANAGEMENT LLC JOHN HANCOCK TOWER, 200 CLARENDON STREET BOSTON, MA 02116		X				
BROOKSIDE CAPITAL INVESTORS L P JOHN HANCOCK TOWER, 200 CLARENDON STREET BOSTON, MA 02116		X				
BROOKSIDE CAPITAL PARTNERS FUND LP JOHN HANCOCK TOWER, 200 CLARENDON STREET BOSTON, MA 02116		X				
Signatures						

Date

/s/ William Edward 02/21/2014 Pappendick, IV

**Signature of Reporting Person

Reporting Owners 2

Edgar Filing: CONCERT PHARMACEUTICALS, INC. - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series B and Series C Convertible Preferred Stock converted into Common Stock on a 1-for-5.65 basis upon the closing of the Issuer's initial public offering without payment of consideration.
- Brookside Capital Management, LLC ("BCM") is the sole general partner of Brookside Capital Investors, L.P. ("BCI"). BCI is the sole general partner of Brookside Capital Partners Fund, L.P. ("BCPF"). BCM and BCI each may be deemed to share voting dispositive powers with respect to the shares held by BCPF. Each of BCM and BCI disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein.
- (3) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.